Get Details: We are Bullish on These 3 Little-known Stocks
Here is the latest financial fact sheet of Dr. Reddys. For more details, see the Dr. Reddys quarterly results and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -0.6 |
No. of shares | m | 165.71 |
% ch week | % | -5.0 |
% ch 1-mth | % | -0.8 |
% ch 12-mth | % | 64.3 |
52 week H/L | Rs | 5,514.7/2,497.6 |
No. of Mths Year Ending |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
5-Yr Chart Click to enlarge
|
---|
DR. REDDYS LAB EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 4,383 | 3,397 | 2,788 | 2,875 | 3,363 | |
Low | Rs | 2,750 | 2,560 | 1,902 | 1,888 | 2,352 | |
Sales per share (Unadj.) | Rs | 912.5 | 856.5 | 860.8 | 930.2 | 1,054.2 | |
Earnings per share (Unadj.) | Rs | 124.9 | 78.0 | 57.1 | 117.4 | 121.9 | |
Diluted earnings per share | Rs | 128.6 | 78.0 | 57.1 | 117.7 | 122.3 | |
Cash flow per share (Unadj.) | Rs | 179.9 | 139.9 | 122.0 | 185.8 | 190.2 | |
Dividends per share (Unadj.) | Rs | 20.00 | 20.00 | 20.00 | 20.00 | 25.00 | |
Adj. dividends per share | Rs | 20.59 | 20.00 | 20.02 | 20.04 | 25.07 | |
Dividend yield (eoy) | % | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | |
Book value per share (Unadj.) | Rs | 736.8 | 739.8 | 757.7 | 844.4 | 938.7 | |
Adj. book value per share | Rs | 758.5 | 740.0 | 758.7 | 846.3 | 941.3 | |
Shares outstanding (eoy) | m | 170.61 | 165.74 | 165.91 | 166.07 | 166.17 | |
Bonus/Rights/Conversions | ESOP | BB | ESOP | ESOP | ESOP | ||
Price / Sales ratio | x | 3.9 | 3.5 | 2.7 | 2.6 | 2.7 | |
Avg P/E ratio | x | 28.6 | 38.2 | 41.1 | 20.3 | 23.4 | |
P/CF ratio (eoy) | x | 19.8 | 21.3 | 19.2 | 12.8 | 15.0 | |
Price / Book Value ratio | x | 4.8 | 4.0 | 3.1 | 2.8 | 3.0 | |
Dividend payout | % | 16.0 | 25.7 | 35.0 | 17.0 | 20.5 | |
Avg Mkt Cap | Rs m | 608,481 | 493,632 | 389,034 | 395,496 | 474,831 | |
No. of employees | `000 | 21.7 | 22.7 | 23.5 | 22.0 | 21.7 | |
Total wages/salary | Rs m | 31,174 | 31,068 | 32,149 | 33,562 | 33,802 | |
Avg. sales/employee | Rs Th | 7,184.6 | 6,259.0 | 6,070.8 | 7,032.8 | 8,091.0 | |
Avg. wages/employee | Rs Th | 1,438.6 | 1,369.8 | 1,366.6 | 1,527.9 | 1,561.3 | |
Avg. net profit/employee | Rs Th | 983.2 | 569.7 | 402.5 | 887.7 | 935.8 |
DR. REDDYS LAB INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 155,683 | 141,961 | 142,810 | 154,482 | 175,170 | |
Other income | Rs m | 2,950 | 1,715 | 1,552 | 3,375 | 6,206 | |
Total revenues | Rs m | 158,633 | 143,676 | 144,362 | 157,857 | 181,376 | |
Gross profit | Rs m | 35,853 | 24,722 | 23,512 | 31,782 | 24,421 | |
Depreciation | Rs m | 9,389 | 10,266 | 10,772 | 11,348 | 11,348 | |
Interest | Rs m | 826 | 634 | 788 | 889 | 983 | |
Profit before tax | Rs m | 28,588 | 15,537 | 13,504 | 22,920 | 18,296 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 229 | 349 | 344 | 438 | 561 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 7,511 | 2,965 | 4,380 | 3,858 | -1,403 | |
Profit after tax | Rs m | 21,306 | 12,921 | 9,468 | 19,500 | 20,260 | |
Gross profit margin | % | 23.0 | 17.4 | 16.5 | 20.6 | 13.9 | |
Effective tax rate | % | 26.3 | 19.1 | 32.4 | 16.8 | -7.7 | |
Net profit margin | % | 13.7 | 9.1 | 6.6 | 12.6 | 11.6 |
DR. REDDYS LAB BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 117,940 | 96,837 | 104,984 | 111,101 | 125,991 | |
Current liabilities | Rs m | 63,471 | 84,199 | 68,938 | 58,973 | 72,141 | |
Net working cap to sales | % | 35.0 | 8.9 | 25.2 | 33.7 | 30.7 | |
Current ratio | x | 1.9 | 1.2 | 1.5 | 1.9 | 1.7 | |
Inventory Days | Days | 60 | 73 | 74 | 79 | 73 | |
Debtors Days | Days | 97 | 98 | 104 | 94 | 105 | |
Net fixed assets | Rs m | 73,352 | 102,552 | 104,385 | 101,245 | 83,854 | |
Share capital | Rs m | 853 | 829 | 830 | 830 | 831 | |
"Free" reserves | Rs m | 124,845 | 121,792 | 124,886 | 139,406 | 155,157 | |
Net worth | Rs m | 125,698 | 122,621 | 125,716 | 140,236 | 155,988 | |
Long term debt | Rs m | 10,685 | 5,449 | 25,089 | 22,000 | 1,304 | |
Total assets | Rs m | 203,841 | 218,165 | 225,443 | 224,656 | 232,253 | |
Interest coverage | x | 35.6 | 25.5 | 18.1 | 26.8 | 19.6 | |
Debt to equity ratio | x | 0.1 | 0 | 0.2 | 0.2 | 0 | |
Sales to assets ratio | x | 0.8 | 0.7 | 0.6 | 0.7 | 0.8 | |
Return on assets | % | 10.9 | 6.2 | 4.5 | 9.1 | 9.1 | |
Return on equity | % | 17.0 | 10.5 | 7.5 | 13.9 | 13.0 | |
Return on capital | % | 21.7 | 12.9 | 9.7 | 14.9 | 12.6 | |
Exports to sales | % | 46.6 | 54.6 | 0 | 0 | 0 | |
Imports to sales | % | 9.0 | 9.4 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 72,618 | 77,520 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 14,050 | 13,274 | 0 | 0 | 0 | |
Fx inflow | Rs m | 75,405 | 81,670 | 72,623 | 88,673 | 84,193 | |
Fx outflow | Rs m | 27,115 | 26,355 | 18,916 | 19,104 | 39,616 | |
Net fx | Rs m | 48,290 | 55,315 | 53,707 | 69,569 | 44,577 |
DR. REDDYS LAB CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 32,626 | 21,444 | 18,030 | 28,704 | 29,841 | |
From Investments | Rs m | -20,394 | -18,404 | -14,883 | -7,727 | -4,923 | |
From Financial Activity | Rs m | -17,001 | -3,692 | -4,440 | -21,326 | -25,159 | |
Net Cashflow | Rs m | -474 | -1,144 | -1,236 | -314 | -266 |
Share Holding
|
Company Information
|
CHM: G. V. Prasad | COMP SEC: Sandeep Poddar | YEAR OF INC: 1984 | BSE CODE: 500124 | FV (Rs): 5 | DIV YIELD (%): 0.5 |
More Pharmaceuticals Company Fact Sheets: TORRENT PHARMA SANOFI INDIA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare DR. REDDYS LAB With: TORRENT PHARMA SANOFI INDIA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Asian stock markets retreated from record highs today as investors took some money off the table after a recent rally that was driven by hopes a massive US economic stimulus plan.
For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More